“Marc Beer- Renovia “

Marc Beer, the founder of Renovia Inc., has opened the door to creating several products for pelvic floor disorders after raising 42 million dollars. Renovia is a company that develops devices that help treat a number of different pelvic floor disorders. All the funding that has been acquired during funding is going towards a line of new products for women’s health.

 

The diagnostic therapy he is developing can treat disorders such as urinary incontinence. This is is something that Renovia’s first product, Leva, can treat.

 

Healthcare investment firms, such as The Longwood Fund, is an early investor in Renovia’s research and products. The funding that is acquired is used to help the development and scientific testing of products that will help diagnosis pelvic floor disorders. Within this development, there is also a creation of a new generation of the Leva device underway.

 

Marc Beer is the founding CEO of ViaCell, a company that focuses on collecting, preserving, and developing umbilical cord stem cells. After seven years of rapid growth, ViaCell went public in 2005 and was eventually bought by PerkinElmer.

 

Before ViaCell, Marc was holding a variety of different positions in a company called Genzyme. In this position. While he was holding a position as CEO of ViaCell, Marc was also holding a position as a member within Erytech Pharma. Erytech Pharma is a publicly traded biopharmaceutical company.

 

Prior to his position at Genzyme, Marc held a number of different positions that centered around sales and marketing at Abbott Laboratories. He was responsible for sales and marketing for the pharmaceutical and diagnostic divisions within the company. During this time, he was also serving as a member of the Mass Life Science Board of Commonwealth of Massachusetts and Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.

 

The other founding positions he was a part of included being a Chairman of Good Start Genetics, which was eventually acquired by InVitae, and being a chairman and member of the audit committee of Minerva Neurosciences Inc.

 

Marc Beer has brought over two decades of the development and global commercialization within the branches of biotech, pharmaceuticals, and diagnostic research. Learn more: https://people.equilar.com/bio/marc-beer-aegerion-pharmaceuticals-/salary/78453

 

“Marc Beer Demonstrates His Expertise in Securing Funding Raising Funds for Boston Women’s Health Startup “

Renovia Inc. recently received a financial boost for the development of several new products for the treatment of pelvic floor disorders with Marc Beer managing to raise $32 million through Series B and $10 million in venture debt. The pharmaceutical startup was co-founded by Marc Beer and it develops various therapeutic and diagnostic products aimed at treating pelvic floor disorders including urinary incontinence in women.

 

According to a research, over 250 million women across the world suffer from urinary incontinence. Renovia is committed to improve the lives of women across the world through pelvic floor disorders therapeutic and diagnostic products. It has manufactured several products including Leva device which received FDA accreditation early last year.

 

The Longwood Fund was among the participants in the financing round which was overseen by the Missouri-based Ascension Ventures as well as New York-based Perceptive Advisors. The Longwood Fund was among the early healthcare firms which invested in Renovia. The Boston-based medtech company is now able to move forward with its four products with development and testing. It will also test and develop a new generation of the Leva device.

 

In a statement, Marc Beer expressed his gratitude with the healthcare investors who have given him unwavering support. He terms that the support he has gotten from the healthcare investors is as a result of their belief in his vision of improving the lives of women across the world who are affected by pelvic floor disorders through development of therapeutic and diagnostic products for the disorders. The Renovia CEO also said that the company using technologies and every resource within its reach to derive understanding of pelvic disorders and inform new treatment options with an ultimate aim of reducing healthcare costs in the long-term.

 

Marc Beer has built a very successful career in the healthcare sector proving to be a useful resource in the sector. He was a strategic consultant at OvaScience (Nasdaq: OVAS), a company which announced that it was merging with Millendo Therapeutics.

 

About Marc Beer

 

Marc Beer brings over 25 years of experience in the healthcare sector. Particularly, he has worked in biotechnology, diagnostics, devices, pharmaceuticals, and diagnostics. He co-founded Marc Beer alongside Ramon Iglesias and Yolanda Lorie. He managed to close Series A financing successfully during its early stages of inception.

 

Marc Beer founded ViaCell and served as CEO for the biotechnology company until it was acquired by PerkinElmer in 2007. The company specialized on acquisition, preservation, as well as development of umbilical blood stem cells. He also was a member of the board of directors of Erytech Pharma. Additionally, he served at Genzyme where he climbed up the ladder to become Vice President of Global Marketing. He held various sales and marketing roles in Abbott Laboratories. He was a member of the Mass Life Science Board of the Commonwealth of Massachusetts. Learn more: https://renoviainc.com/leadership/

 

Mark Beer Renovia

Mark Beer grew up in Ohio where he studied at the Miami University graduating with the Bachelor Science. The individual qualifies with over 25 years of experience in development and commercialization in devices, diagnostic, pharmaceutical, and biotechnology. Together with Yolanda Lurie and Roman Iglesias, Beer established the Renovia Inc in August 2016. Soon after the establishment, the leaders completed a Series A funding round. Renovia is a demonstration of a line of various successful establishments of Beer. The primary focus and developments of beer touch on technological convergences and medicine.

 

Every individual trusts Mark Beer as the optimal leader of Renovia considering his level of experience and accomplishment and the leadership positions he held before. Beer and his team completed a $42-million Series B funding that showed significant improvement not just for Renovia but for Beer. Beer garnered leadership skills and attention after becoming the founder and the CEO of ViaCell. The biotechnology company manages the preservation, collection, and development of the umbilical cord stem cells. The biotech company went public in 2005 after garnering more than 300 workers. Later, after two years, Perkin Elmer took the possession of ViaCell. Before he became the CEO of ViaCell, Mark Beer served in various leadership positions including the executive vice president of global marketing. Every position Beer held would open up much experience not just in medicine but knowing what people need, especially when working at Renovia.

 

The finishing of the Series B funding round will help in reinforcing the growth of medical technology devices meant to treat, diagnose, and prevent pelvic floor disorders, such as the urinary incontinence. As the CEO, Mark Beer expressed appreciations to every individual who took part in development to allow the Boston-base MedTech Company to enhance on its existing products and come up with new ones. All the uniqueness in treating and diagnosing the pelvic floor disorders of Renovia get attributed to Beer through his experience and high level of education and expertise.

 

The primary focus of Renovia is to enhance the technology that will assist women to perform the exercise accurately to straighten their pelvic floor muscles. Much of the cash received from the Series B funding round will get used in developing and testing of four other therapeutic and diagnostic products that include a new version of Leva pelvic digital health system. Also, the fund will assist in future commercial launches, corporate development, product development, and setting up new clinical trials.

 

The new research trails will help to determine the improvement of women who use the Leva device for strengthening pelvic floor muscle as compared to those who do not use the technology. The trail was to start in August 2018, and the company expected a turn up of over 260 women. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues